| NCT ID | NCT07127510 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Florida Atlantic University |
| Condition | Alzheimer Disease (AD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-03-18 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2026-03-18 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease. Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
Eligibility Criteria
Inclusion Criteria: * Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory. * Age 65 to 80 included. * People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test. Exclusion Criteria: * Under the age of 65 or over the age of 80. * Advanced dementia such that the person would require sedation for undergoing an MRI scan. * Receiving anti-amyloid intravenous treatments Leqembi or Kinsula. * Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part). * Having a history of seizures. * Working at night. * Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer). * People with no AD: MoCA test result lower than 26.
Contact & Investigator
Corinne Lasmezas, PhD
PRINCIPAL INVESTIGATOR
Florida Atlantic University
Frequently Asked Questions
Who can join the NCT07127510 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 80 Years, studying Alzheimer Disease (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07127510 currently recruiting?
Yes, NCT07127510 is actively recruiting participants. Contact the research team at CRUDOR@health.fau.edu for enrollment information.
Where is the NCT07127510 trial being conducted?
This trial is being conducted at Boca Raton, United States.
Who is sponsoring the NCT07127510 clinical trial?
NCT07127510 is sponsored by Florida Atlantic University. The principal investigator is Corinne Lasmezas, PhD at Florida Atlantic University. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.